Cellectis S.A.
CLLS
$3.62
$0.123.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.76% | 158.90% | 332.15% | 825.97% | 5,397.35% |
| Total Other Revenue | -13.85% | 4.49% | 8.05% | 1.80% | -8.61% |
| Total Revenue | 61.72% | 129.04% | 223.06% | 351.22% | 435.32% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 61.72% | 133.82% | 235.66% | 380.41% | 481.97% |
| SG&A Expenses | 3.69% | 5.82% | 17.74% | 10.21% | 13.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 24.85% | -1.79% | -31.64% | -125.45% | -110.15% |
| Total Operating Expenses | 3.58% | -3.83% | 1.75% | 1.79% | 3.80% |
| Operating Income | 44.46% | 65.82% | 48.12% | 43.52% | 37.70% |
| Income Before Tax | -85.02% | 59.01% | 26.13% | 27.60% | 68.44% |
| Income Tax Expenses | -- | 201.18% | 232.65% | 142.59% | -100.00% |
| Earnings from Continuing Operations | -83.87% | 58.15% | 25.23% | 27.38% | 68.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.87% | 58.15% | 25.23% | 7.36% | 63.62% |
| EBIT | 44.46% | 65.82% | 48.12% | 43.52% | 37.70% |
| EBITDA | 54.93% | 79.14% | 56.92% | 50.77% | 43.59% |
| EPS Basic | -81.85% | 66.81% | 48.81% | 41.86% | 78.72% |
| Normalized Basic EPS | -195.22% | 76.00% | 53.09% | 53.82% | 85.42% |
| EPS Diluted | -12.23% | 72.45% | 57.08% | 51.77% | 65.52% |
| Normalized Diluted EPS | -168.83% | 76.60% | 54.19% | 54.79% | 83.99% |
| Average Basic Shares Outstanding | 10.34% | 22.02% | 41.14% | 57.36% | 58.98% |
| Average Diluted Shares Outstanding | 1.92% | 11.76% | 27.08% | 39.75% | 72.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |